



## CEBPA Mutation by PCR

Order Name: **CEBPA PCR**  
Test Number: 9616990  
Revision Date: 01/24/2025

TEST NAME	METHODOLOGY	LOINC CODE
<b>CEBPA Mutation by PCR</b>	<u>Polymerase Chain Reaction</u>	

SPECIMEN REQUIREMENTS				
Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment
Preferred	<b>5 mL (3 mL)</b>	<b>Whole Blood</b>	<b>EDTA (Lavender Top)</b>	<b>Room Temperature</b>
Alternate 1	<b>5 mL (3 mL)</b>	<b>Whole Blood</b>	<b>Sodium Heparin (Green Top / No-Gel)</b>	<b>Room Temperature</b>
Alternate 2	<b>2 mL (1 mL)</b>	<b>Bone Marrow</b>	<b>EDTA (Lavender Top)</b>	<b>Room Temperature</b>
Alternate 3	<b>2mL (1mL)</b>	<b>Bone Marrow</b>	<b>Sodium Heparin (Green Top / No-Gel)</b>	<b>Room Temperature</b>
Instructions	<b>Specimen:</b> 5mL(3mL) Whole Blood or 2mL (1mL) Bone Marrow <b>Container:</b> Lavender-top (EDTA) tube, green-top (sodium heparin) tube <b>Collection:</b> Indicate date and time of collection on the test request form. Submit specimen at room temperature ASAP, Keep at room temperature! (DO NOT FREEZE). Frozen samples will be rejected. <b>Storage Instructions:</b> Maintain specimen at room temperature. If specimen is to be stored prior to shipment, store at 2°C to 8°C. <b>Cause for Rejection:</b> Specimen does not meet all of the above criteria for sample type, container, minimum volume, collection and storage; unsuitable specimens include but are not limited to: frozen whole blood or marrow; a leaking tube; clotted blood or marrow; a grossly hemolyzed specimen or otherwise visibly degraded; specimen suspected of being contaminated by another specimen; specimen contains specific foreign material.			

GENERAL INFORMATION	
Testing Schedule	Mon- Fri
Expected TAT	12-14 Days from set up.
Clinical Use	Determine prognosis in cytogenetically normal acute myelogenous leukemia (CN-AML) The CEBPA (CCAAT/enhancer binding protein ) gene encodes a transcription factor important for granulocyte differentiation. CEBPA mutations are found in 6% to 15% of de novo acute myeloid leukemia (AML) and in 15% to 18% of AML with normal karyotypes. CEBPA mutations are associated with favorable prognosis in the absence of associated cytogenetic abnormalities and FLT3 internal duplication (FLT3-ITD). Germline CEBPA mutations are a cause of nonsyndromic, familial AML.
CPT Code(s)	81218
Service Provided By	 <b>labcorp</b> Oklahoma, Inc.